TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06279156

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioelectrical Impedance Analysis (BIA)
Description: Measure BIA for patients' dry weight to compare between measuring every-1-month or every-2-month.~In brief, BIA is the machine used for measure body components such as fat, muscle, and free water. It relies on the principle of using the multifrequency of low electric currents to the body and measurement of the ability of the electrical currents passing different body composition. Thus, the machine can calculate back for the amount of each body composition.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioelectrical Impedance Analysis (BIA)
Description: Measure BIA for patients' dry weight to compare between measuring every-1-month or every-2-month.~In brief, BIA is the machine used for measure body components such as fat, muscle, and free water. It relies on the principle of using the multifrequency of low electric currents to the body and measurement of the ability of the electrical currents passing different body composition. Thus, the machine can calculate back for the amount of each body composition.
Study: NCT06329167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daphnetin
Description: 150mg tid (3 capsules/time, 3 times daily) and gradient compression stockings.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aescuven
Description: 150mg (2 capsules/time, 2 times daily) and gradient compression stockings.
Study: NCT05276739

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bright Light
Description: 6.5-hour 10,000 lux light pulse (4100K fluorescent light) centered within the 16-hour wake episode (start 4.75 hour after wake and end 11.25 hour after wake).
Study: NCT06098768

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: VR Social Skills
Description: The intervention will consist of two episodes of the Floreo BSC program, each lasting 4-5 minutes, according to a fixed program of episodes determined by the participant's color-coded group. VR episodes will be presented via the Floreo application downloaded onto an iPhone worn by the participant in the VR headset. The VR interaction will be controlled and operated via linked iPad.
Study: NCT05382975

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CSPAP-T
Description: Trauma-adapted CSPAP delivery:~* Staffing support~* Trauma-sensitive professional development for teachers and staff~* Setting specific needs assessment and action planning
Study: NCT05276739

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted eating
Description: 6.5-hour restricted meal window (4 meals at 4.75, 6.9, 9.1, 11.25 hours after waking) centered within the 16-hour wake episode.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Dim light
Description: dim light (\<3 lux) throughout the 16-hour wake episode

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dim light
Description: dim light (\<3 lux) throughout the 16-hour wake episode
Study: NCT05382975

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CSPAP-T
Description: Trauma-adapted CSPAP delivery:~* Staffing support~* Trauma-sensitive professional development for teachers and staff~* Setting specific needs assessment and action planning

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CSPAP-T
Description: Trauma-adapted CSPAP delivery:~* Staffing support~* Trauma-sensitive professional development for teachers and staff~* Setting specific needs assessment and action planning
Study: NCT05276739

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-h meal window
Description: 12-hour restricted meal window (4 meals at 2, 6, 10, and 14 hours after waking) centered within the 16-hour wake episode.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: 12-h meal window
Description: 12-hour restricted meal window (4 meals at 2, 6, 10, and 14 hours after waking) centered within the 16-hour wake episode.
Study: NCT04889300

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Best Possible Self
Description: Participants are asked to think about their Best Possible Self for one minute, then describe it for 15 minutes (in writing) and, subsequently, imagine it for another 5 minutes as vividly as possible.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Typical Day
Description: Participants are asked to think about their Typical Day for one minute, then describe it for 15 minutes (in writing) and, subsequently, imagine it for another 5 minutes as vividly as possible.
Study: NCT05583929

Intervention type: OTHER
Intervention: GAITRite gaitway system, Bertec Balance System
Description: GAITRite gaitway system will use to assess gait parameters, Bertec Balance System will use to assess limit of stability

Intervention type: OTHER
Intervention: GAITRite gaitway system, Bertec Balance System
Description: GAITRite gaitway system will use to assess gait parameters, Bertec Balance System will use to assess limit of stability
Study: NCT05382637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin
Description: Daily growth hormone at a starting dose of 50 mcg/kg/day and escalating
Study: NCT05808400

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC-derived exosomes
Description: The total volume of MSC-derived exosomes is 5ml, and exosome concentration in preparation is 1\*10\^9 particles/ml.
Study: NCT05754814

Intervention type: OTHER
Intervention: Malignant lymph nodes
Description: Patients with a condition; either lymphoma on the neck or head and neck cancer with lymph node metastases on the neck.
Study: NCT05683067

Intervention type: OTHER
Intervention: Hand Held Capillary Microscopy
Description: The investigator will visualize the blood vessel appearance, number, and size they have in their hands, feet, and under the tongue. This procedure is non-invasive and will not cause any pain.

Intervention type: OTHER
Intervention: Hand Held Capillary Microscopy
Description: The investigator will visualize the blood vessel appearance, number, and size they have in their hands, feet, and under the tongue. This procedure is non-invasive and will not cause any pain.

Intervention type: OTHER
Intervention: Hand Held Capillary Microscopy
Description: The investigator will visualize the blood vessel appearance, number, and size they have in their hands, feet, and under the tongue. This procedure is non-invasive and will not cause any pain.

Intervention type: OTHER
Intervention: Mobile 'O' Graph
Description: The aortic stiffness will be measured non-invasively using a special blood pressure monitor called Mobile 'O' Graph, which is about size of a pocket diary. 24 hour blood pressure monitoring is optional.

Intervention type: OTHER
Intervention: Mobile 'O' Graph
Description: The aortic stiffness will be measured non-invasively using a special blood pressure monitor called Mobile 'O' Graph, which is about size of a pocket diary. 24 hour blood pressure monitoring is optional.

Intervention type: OTHER
Intervention: Mobile 'O' Graph
Description: The aortic stiffness will be measured non-invasively using a special blood pressure monitor called Mobile 'O' Graph, which is about size of a pocket diary. 24 hour blood pressure monitoring is optional.

Intervention type: OTHER
Intervention: quality of life using questionnaires
Description: The investigator will evaluate the quality of life using questionnaires such as EQ-5D-5L questionnaire and the Minnesota Living with Heart Failure Questionnaire (MLHFQ)

Intervention type: OTHER
Intervention: quality of life using questionnaires
Description: The investigator will evaluate the quality of life using questionnaires such as EQ-5D-5L questionnaire and the Minnesota Living with Heart Failure Questionnaire (MLHFQ)
Study: NCT06239987

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care-oriented Practical Training
Description: The training content includes evidence-based practice recommendations for intensive and critical care, hand hygiene, hygiene practices in patients with special needs, and prevention and control of common HAIs. In the first stage of the training, practical training will be given by the intensive care coordinator and infection control nurse on the application model. In the second stage, patient care practices of a care team consisting of an intensive care nurse and care support staff will be observed. The training will be conducted interactively with narration, demonstration and question and answer techniques.
Study: NCT05683067

Intervention type: OTHER
Intervention: quality of life using questionnaires
Description: The investigator will evaluate the quality of life using questionnaires such as EQ-5D-5L questionnaire and the Minnesota Living with Heart Failure Questionnaire (MLHFQ)
Study: NCT05403918

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physiotherapy
Description: Hot pack, TENS, and therapeutic ultrasound will be applied for 10 minutes. Then glides will be given 30 x 3 times in grades III and IV. The rest of the exercises will be prescribed as 3 sets for 10 repetitions with 2 minutes of rest between sets for 6 weeks with respect to 3 sessions per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scapular stabilization exercises along with conventional physiotherapy
Description: Each stretch will be repeated 3 times. Each active exercise will be progressed from 3 sets of 10 reps to 3 sets of 15 reps. If the subject easily completed 3 sets of 15 reps of active exercise, they will go on to resisted exercises. These will be performed once a day, for 6 weeks, 3 sessions per week.
Study: NCT05648279

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized hemodynamic management
Description: Personalized hemodynamic management: Intraoperative cardiac index will be maintained at least at the preoperative baseline cardiac index. Preoperative baseline cardiac index will be determined one day before surgery with the patient being awake and resting in the supine position using the Starling Fluid Management System (Baxter, Deerfield, IL, USA). We will define the individual preoperative baseline cardiac index as the average value over a 5 min period at rest (minimum cardiac index threshold: 2.2 L min-1 m-2). Intraoperative cardiac index will be measured using the Baxter Starling Fluid Management System.
Study: NCT04920669

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: erector spinae block with bupivacaine
Description: Patients will receive a sonar-guided erector spinae plane block with 20 ml of bupivacaine 0.5%

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: erector spinae block with bupivacaine + dexmedetomidine
Description: Patients will receive a sonar-guided erector spinae plane block with 19 ml of bupivacaine 0.5%+ 1 ml dexmedetomidine
Study: NCT05006469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine 70-90mg/m2, d1, d2 Liposome Adriamycin 15-20mg/m2, d1 or Adriamycin 10mg d1-d4 Dexamethasone 40mg qw po. (20mg, \>70 years old) There is a course of treatment every 28 days, and a total of 6 courses are completed.
Study: NCT05366686

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NICE Support Program
Description: Patients in experimental group will receive a 12 week NICE Support program; patients in control group maintain their usual life activities.
Study: NCT05364242

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VLA2001
Description: whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG)1018 in combination with aluminium hydroxide
Study: NCT04677244

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sample in portal vein
Description: A 6 ml blood sample will be taken from the portal vein, before and after the echo-endoscopic biopsy of the pancreatic mass. The second sample will be taken after the biopsy if there is no bile drainage, or after bile drainage if indicated. The delay between the end of the biopsy procedure and the puncture will be 5 minutes. A 6 ml peripheral blood sample will also be taken before and after the endoscopic procedure.
Study: NCT04670926

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Patient's immunosuppression will be managed per the current CPMC standard of care that includes continuation of Mycophenolate Mofetil or Mycopheonolate Sodium at 1000 mg bid or 720 mg bid respectively. The dose may be decreased at the discretion of the physician for drug adverse effects such as diarrhea or other gastrointestinal side-effects or neutropenia as is the standard of care. Patients will be maintained on Tacrolimus at target levels that are considered standard of care by the managing physician.
Study: NCT05664087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dental diode laser device Paiwei™（Zhengzhou Gata biotechnology Co.,Ltd.,China） which was 650-670nm with a power of 160mw-220mw.
Description: The tooth extraction sockets were filled with photosensitizer methylene blue. The guide head of the laser periodontal therapy instrument (Dental diode laser device Paiwei™（Zhengzhou Gata biotechnology Co.,Ltd.,China） which was 650-670nm with a power of 160mw-220mw.) was placed in the tooth extraction sockets to probe and move around the tooth extraction sockets for 1 minute. At the end of irradiation, a cotton ball dipped in saline was used to wipe the guide head and rinse the photosensitizer out of the socket
Study: NCT05804708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GH001
Description: GH001 is administered via inhalation
Study: NCT04699487

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: Oral pads will be applied on irradiated areas presenting a risk of radiotherapy-related OM. In addition, a derma pad will be applied on the anterior face of the neck to protect the oropharynx from OM.~The dose to be delivered, at each session and each applied area, has been set at 3 J/cm². In case a lesion appears, the dose will be increased to 6J/cm² for curative treatment.~Treatment with CareMin650 must start on the first day of radiotherapy and will be administered during the whole radiotherapy period, ideally 5 days/week, at least 3 days/week, ideally before the radiotherapy session.
Study: NCT05903183

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVX-A12
Description: IVX-A12 without adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVX-A12
Description: IVX-A12 with adjuvant

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Diluent
Study: NCT05148923

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct current cardioversion (DCCV)
Description: DCCV is a safe and effective method of treating atrial fibrillation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct current cardioversion (DCCV)
Description: DCCV is a safe and effective method of treating atrial fibrillation.
Study: NCT05469347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: A 600 mg dose of alirocumab (which is equivalent to 8mg/kg for a 75kg patient) will be administered once via IV over an approximately 30 ± 10 minute infusion using an infusion pump.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo to match a 600 mg dose of alirocumab will be administered once via IV over an approximately 30 ± 10 minute infusion using an infusion pump.
Study: NCT05352152

Intervention type: DIAGNOSTIC_TEST
Intervention: Next generation sequence
Description: Next generation sequence will be used to detect the pathogens in ascites.
Study: NCT05813912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Icodec
Description: Participants will receive subcutaneously insulin icodec once weekly for 52 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive once weekly semaglutide subcutaneously starting from 0.25 mg and dose increased up to 1 mg for 26 weeks.
Study: NCT05877482

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short foot exercises
Description: A total of 26 participants with pes planus were assigned to the short-foot exercises group (n = 13) and the control group (n = 13). Both groups will be informed about pes planus, usual foot care, and appropriate footwear with foot insoles. In experimental group Short foot exercises (SFE) and internal shoe modification will be performed by placing a medial longitudinal arch support insoles inside the shoe. Exercises will be performed daily for six weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insoles
Description: In control group only internal shoe modification will be performed by placing medial longitudinal arch support insoles inside the shoe. Group assignment and SFE training will be conducted by the second physical therapist to provide blindness.
Study: NCT05598099

Intervention type: BEHAVIORAL
Intervention: Concentrated cognitive behavioral therapy
Description: A psychological intervention consisting of psychoeducation and exposure therapy with the goal of changing the tolerability and negative interpretations of post-traumatic symptoms. The treatment is tailored to the individual patient through all stages, including relapse prevention and planning how to use treatment principles in daily life

Intervention type: BEHAVIORAL
Intervention: Concentrated cognitive behavioral therapy
Description: A psychological intervention consisting of psychoeducation and exposure therapy with the goal of changing the tolerability and negative interpretations of post-traumatic symptoms. The treatment is tailored to the individual patient through all stages, including relapse prevention and planning how to use treatment principles in daily life
Study: NCT06341920

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: BoneFit intervention
Description: Exercise, nutrition and psychological support provided in 8 weeks prior to surgery

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Control
Description: Control group receive usual care (zero intervention)
Study: NCT04829435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALLN-346
Description: ALLN-346 (Engineered Urate Oxidase) is an orally administered, novel urate oxidase; provided as capsules for oral administration; It is a proprietary enzyme designed to degrade urate in the intestinal tract
Study: NCT05231382

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Raltitrexed, oxaliplatin (SALOX) treatment
Description: Hepatic arterial infusion (HAI) of Raltitrexed, oxaliplatin (SALOX) treatment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment
Description: Hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment
Study: NCT06294457

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Invasive Neuromodulation NESA
Description: Considering the objectives set: In the first phase, the directing electrode will be located at C6-C7 to generate a systemic and general effect on the organism, with program 1, program 2, program 7, and program 8. In the second phase, the directing electrode will be placed at the abdominal level in the area of the mesenteric plexus to influence the sympathetic innervation of the viscera. In the third phase, the directing electrode is located at S2-S3 to concentrate the action of the therapy on the sacral parasympathetic plexus, responsible for the innervation of the rectum. In this way, both the sympathetic and parasympathetic innervation of the main sexual organs and the large intestine are covered through the sympathetic paravertebral ganglia and the sacral plexus.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Non-Invasive Neuromodulation NESA
Description: Considering the objectives set: In the first phase, the directing electrode will be located at C6-C7 to generate a systemic and general effect on the organism, with program 1, program 2, program 7, and program 8. In the second phase, the directing electrode will be placed at the abdominal level in the area of the mesenteric plexus to influence the sympathetic innervation of the viscera. In the third phase, the directing electrode is located at S2-S3 to concentrate the action of the therapy on the sacral parasympathetic plexus, responsible for the innervation of the rectum. In this way, both the sympathetic and parasympathetic innervation of the main sexual organs and the large intestine are covered through the sympathetic paravertebral ganglia and the sacral plexus.
Study: NCT04795557

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ADAPT-232 oral solution
Description: One ml of ADAPT 232/CHISAN oral solution contains:~Fructus Schizandrae native extract DERnative 2-4:1, (extraction solvent . 95% ethanol) - 10 mg corresponding to 20-40 mg dried fruit; Radix Eleutherococci native extract DERnative 17-30:1 (extraction solvent - 70% ethanol) - 2.6 mg corresponding to 44-78 mg dried rhizomes, and Radix Rhodiolae native extract DERnative 2-5:1 (extraction solvent - 70% ethanol) - 3 mg corresponding to 6-30 mg dried rhizomes.~Excipients

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral solution
Description: Excipients
Study: NCT05618821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green Tracer
Description: Laparoscopic gastrectomy with lymph node dissection for remnant gastric cancer using Indocyanine Green Tracer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indocyanine Green Tracer
Description: Laparoscopic gastrectomy with lymph node dissection for remnant gastric cancer using Indocyanine Green Tracer
Study: NCT04839380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruxolitinib cream
Description: ruxolitinib cream 1.5% will be applied twice daily as a thin film
Study: NCT04697485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bumetanide 0.5 mg, dapaglifozin 5 mg, eplerenone 25 mg
Description: Low-Dose, Triple Polydiuretic Therapy (LDTPT) Treatment consists of:~* Loop diuretic (bumetanide 0.5 mg)~* Mineralocorticoid receptor antagonist (eplerenone 25 mg)~* Sodium-glucose co-transporter 2 inhibitor (SGLT2i): Farxiga® (dapagliflozin) 5 mg
Study: NCT05082103

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enzyme lozenge 1
Description: Participants are instructed to take one enzyme containing lozenge three times daily, at least 30 min after a meal, for 14 days. No normal oral hygiene procedures are allowed during the intervention period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enzyme lozenge 2
Description: Participants are instructed to take one lozenge with 3x higher enzyme concentration three times daily, at least 30 min after a meal, for 14 days. No normal oral hygiene procedures are allowed during the intervention period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo lozenge
Description: Participants are instructed to take one placebo lozenge three times daily, at least 30 min after a meal, for 14 days. No normal oral hygiene procedures are allowed during the intervention period.